Bifidobacterium(Nitto Pharmaceutical Industries Ltd.)(Bifidobacterium(Nitto Pharmaceutical Industries Ltd.))

概要

基本信息

药物类型

益生菌

别名

Bifisgen、ビフィスゲン

靶点-

作用机制

细菌替代物、微生物调节剂

治疗领域

其他疾病

在研适应症

菌群失调

非在研适应症-

原研机构

Nitto Pharmaceutical Industries Ltd.

在研机构

Nitto Pharmaceutical Industries Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1969-05-01),

菌群失调

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

17

项与 Bifidobacterium(Nitto Pharmaceutical Industries Ltd.) 相关的临床试验

ChiCTR2200062996 / Suspended临床4期IIT

Clinical study of live combined Bifidobacterium and Lactobacillus tablets regulating gut microbiota to prevent post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy

开始日期2022-09-01

申办/合作机构-

JPRN-jRCTs021210038 / RecruitingN/AIIT

Efficacy of Bifidobacterium Agent on Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial - IBS-Bb-RCT

开始日期2022-04-04

申办/合作机构-

ChiCTR2100052510 / Suspended临床4期IIT

Efficacy and safety of Bifidobacterium triple viable capsules in allergic rhinitis intervention: A randomized, double-blind, placebo-controlled trial

开始日期2022-01-01

申办/合作机构

上海市同济医院

100 项与 Bifidobacterium(Nitto Pharmaceutical Industries Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Bifidobacterium(Nitto Pharmaceutical Industries Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Bifidobacterium(Nitto Pharmaceutical Industries Ltd.) 相关的专利（医药）

登录后查看更多信息

39

项与 Bifidobacterium(Nitto Pharmaceutical Industries Ltd.) 相关的文献（医药）

2024-12-31·Gut Microbes

Bifidobacterium alleviate metabolic disorders via converting methionine to 5’-methylthioadenosine

Article

作者: Lyu, Qiang ; Hsu, Cheng-Chih ; Wu, Wei-Kai ; Cheng, Wan-Ju ; Liu, Lihong ; Wu, Ming-Shiang ; Chen, Rou-An ; Zou, Hsin-Bai ; Chuang, Hsiao-Li ; Wu, Hsin-Yi ; Chang, Hsin-Yuan ; Liu, Po-Yu ; Sung, Li-Kang

Dietary patterns and corresponding gut microbiota profiles are associated with various health conditions. A diet rich in polyphenols, primarily plant-based, has been shown to promote the growth of probiotic bacteria in the gastrointestinal tract, subsequently reducing the risk of metabolic disorders in the host. The beneficial effects of these bacteria are largely due to the specific metabolites they produce, such as short-chain fatty acids and membrane proteins. In this study, we employed a metabolomics-guided bioactive metabolite identification platform that included bioactivity testing using in vitro and in vivo assays to discover a bioactive metabolite produced from probiotic bacteria. Through this approach, we identified 5'-methylthioadenosine (MTA) as a probiotic bacterial-derived metabolite with anti-obesity properties. Furthermore, our findings indicate that MTA administration has several regulatory impacts on liver functions, including modulating fatty acid synthesis and glucose metabolism. The present study elucidates the intricate interplay between dietary habits, gut microbiota, and their resultant metabolites.

2024-10-01·Naunyn-Schmiedeberg's Archives of Pharmacology

Study on the mechanism of hirudin multi target delaying renal function decline in chronic kidney disease based on the “gut-kidney axis” theory

Article

作者: Long, Chunli ; Xie, Yongxiang ; Zhang, Chenyun

AbstractThe disorder of the “gut-kidney axis” exacerbates renal function decline in chronic kidney disease (CKD), and current CKD therapy is insufficient to address this issue. Hirudin has a palliative effect on the decline of renal function. However, whether hirudin can delay CKD by regulating the “intestinal renal axis” disorder remains unclear. Unilateral ureteral ligation (UUO) induced CKD rat model, and the rats were treated with bifidobacterium and hirudin for 36 days. After 14 and 36 days of modeling, kidney and colon tissues were collected for pathology, western blot (WB) assay, and quantitative real-time PCR (qPCR) detection. Serum samples were collected for renal function testing. Fecal samples were used for 16S rRNA sequencing and research on fecal bacterial transplantation. Lipopolysaccharide combine with adenosine 5’-triphosphate (LPS + ATP)-induced intestinal epithelial cell injury was treated with a nod-like receptor pyrin domain-associated protein 3 (NLRP3) inhibitor and hirudin. Protein expression was detected using WB and qPCR. The kidneys and colons of the CKD rats exhibited varying degrees of lesions. Creatinine (CRE), blood urea nitrogen (BUN), N-acetyl-β-D-glucosidase (NAG) enzyme, and serum uremic toxins were elevated. The expression of claudin-1 and occludin was decreased, NLRP3 inflammatory-related proteins were increased, and the gut microbiota was disrupted. These pathological changes were more pronounced after 36 days of modeling. Meanwhile, high-dose hirudin treatment significantly improved these lesions and restored the intestinal flora to homeostasis in CKD rats. In vitro, hirudin demonstrated comparable effects to NLRP3 inhibitors by upregulating claudin-1 and occludin expression, and downregulating NLRP3 inflammatory-related proteins expression. The dysbiosis of the gut microbiota and impaired intestinal epithelial barrier function in CKD are associated with renal dysfunction in CKD. Hirudin delays the progression of CKD by regulating the disorder of the “gut-kidney axis” and inhibiting the activation of the NLRP3-ASC-caspase-1 pathway.

2024-08-17·Journal of the American Nutrition Association

Effect of Bifidobacterium Intake on Body Weight and Body Fat in Overweight and Obese Adult Subjects: A Systematic Review and Meta-Analysis

Review

作者: González-Clavijo, Angélica ; Martínez-Solarte, Miguel Angel ; Hamed Riveros, Nicolás Farid ; García-Corredor, Lady

This systematic review aimed to assess the impact of Bifidobacterium genus probiotics on body weight and body composition parameters in overweight and obese individuals.A systematic search for randomized controlled trials was conducted in MEDLINE, EMBASE, LILACS, and Google Scholar databases until April 17, 2023. The inclusion criteria required the trials to involve Bifidobacterium genus probiotics interventions and the evaluation of obesity-related anthropometric and body composition outcomes in overweight or obese subjects. Studies were excluded when involving obese individuals with genetic syndromes or pregnant women, as well as probiotic mixture interventions. The revised Cochrane risk-of-bias tool for randomized trials was utilized to assess the quality of the included studies. A random-effects meta-analysis was performed using the mean difference between endpoint measurements and change from baseline for body mass index, body weight, body fat mass, body fat percentage, waist circumference, waist-to-hip ratio, and visceral fat area.From 1,527 retrieved reports, 11 studies (911 subjects) were included in this review. Bifidobacterium probiotics administration resulted in significant reductions in body fat mass (MD = -0.64 kg, 95% CI: -1.09, -0.18, p = 0.006), body fat percentage (MD = -0.64%, 95% CI: -1.18, -0.11, p = 0.02), waist circumference (MD = -1.39 cm, 95% CI: -1.99, -0.79, p < 0.00001), and visceral fat area (MD = -4.38 cm², 95% CI: -7.24, -1.52, p = 0.003). No significant differences were observed for body mass index, body weight, or waist-to-hip ratio.This systematic review suggests that Bifidobacterium genus probiotics may contribute to managing overweight and obesity by reducing body fat mass, body fat percentage, waist circumference, and visceral fat area. Further research is required to understand strain and species interactions, optimal dosages, and effective delivery methods for probiotics in obesity management. This review was pre-registered under the PROSPERO record CRD42022370057.

100 项与 Bifidobacterium(Nitto Pharmaceutical Industries Ltd.) 相关的药物交易

登录后查看更多信息